Tourmaline Bio

Developing transformative medicines that dramatically improve the lives of patients with immune & inflammatory diseases

Add To Watchlist
General Information
Company Name
Tourmaline Bio
Founded Year
2021
Location (Offices)
New York, United States +1
Founders / Decision Makers
Ryan Robinson - CFO Susan D. Jones - Chief Technology Officer Sandeep Kulkarni - Co-Founder and Chief Executive Officer Gerhard Hagn - Senior Vice President and Head of Commercial and Business Development
Number of Employees
77
Industries
Biotechnology, Health and Wellness
Funding Stage
Post Ipo Equity
Social Media

Tourmaline Bio - Company Profile

Tourmaline Bio, a late-stage clinical biotechnology company, is dedicated to developing transformative medicines that can significantly improve the lives of patients dealing with life-altering immune and inflammatory diseases. The company is on a mission to establish new standards-of-care in areas of high unmet medical need by driving the development of assets with immense potential. Founded in 2021 and headquartered in the United States, Tourmaline Bio recently secured a $172.50M Post-IPO Equity investment on 25 January 2024, marking a pivotal moment for the company's growth and advancement in the biotechnology industry.

Taxonomy: clinical trials, immune diseases, inflammatory diseases, transformational medicines, patient-focused, asset development, unmet medical need

Funding Rounds & Investors of Tourmaline Bio (4)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $172.50M - 25 Jan 2024
Post-IPO Equity $75.00M 10
Qiming Venture Partners USA, investor in Tourmaline Bio's Post-IPO Equity round Affinity Asset Advisors, investor in Tourmaline Bio's Post-IPO Equity round Cowen Digital, investor in Tourmaline Bio's Post-IPO Equity round Deep Track Capital, investor in Tourmaline Bio's Post-IPO Equity round Logos Capital, investor in Tourmaline Bio's Post-IPO Equity round TCG Crossover, investor in Tourmaline Bio's Post-IPO Equity round Paradigm BioCapital Advisors, investor in Tourmaline Bio's Post-IPO Equity round Braidwell, investor in Tourmaline Bio's Post-IPO Equity round StemPoint Capital, investor in Tourmaline Bio's Post-IPO Equity round
Acuta Capital Partners 		19 Oct 2023
Series A $112.00M - 01 Jan 2023
Seed Round Unknown - 01 May 2022

Latest News of Tourmaline Bio

View All

No recent news or press coverage available for Tourmaline Bio.

Similar Companies to Tourmaline Bio

View All
UNITY Biotechnology - Similar company to Tourmaline Bio
UNITY Biotechnology
ACEA Therapeutics, Inc - Similar company to Tourmaline Bio
ACEA Therapeutics, Inc Committed to improving the lives of patients with chronic and life-threatening diseases.
Structure Therapeutics - Similar company to Tourmaline Bio
Structure Therapeutics Creating innovative, life-changing medicines for patients using advanced computational and structure-based technology.
MoonLake Immunotherapeutics (NASDAQ: MLTX) - Similar company to Tourmaline Bio
MoonLake Immunotherapeutics (NASDAQ: MLTX) Creating next-level therapies for inflammatory skin and joint diseases with Nanobody® science
ServareGMP - Similar company to Tourmaline Bio
ServareGMP ServareGMP’s objective is to use its capabilities to meet the needs of the underserved, the neglected and the vulnerable
Circle Decoration Circle Decoration

Want to dive deeper into Tourmaline Bio? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now